#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Thalamic cortical error-related responses in adult social drinkers: sex differences and problem alcohol use Background Error-related brain activities are altered in individuals with substance use disorders.
1-1	0-8	Thalamic	_
1-2	9-17	cortical	_
1-3	18-31	error-related	_
1-4	32-41	responses	_
1-5	42-44	in	_
1-6	45-50	adult	_
1-7	51-57	social	_
1-8	58-66	drinkers	_
1-9	67-68	:	_
1-10	69-72	sex	_
1-11	73-84	differences	_
1-12	85-88	and	_
1-13	89-96	problem	_
1-14	97-104	alcohol	_
1-15	105-108	use	_
1-16	109-119	Background	_
1-17	120-133	Error-related	_
1-18	134-139	brain	_
1-19	140-150	activities	_
1-20	151-154	are	_
1-21	155-162	altered	_
1-22	163-165	in	_
1-23	166-177	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-24	178-182	with	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-25	183-192	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-26	193-196	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-27	197-206	disorders	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-28	207-208	.	_

Text=Here we examined error-related activities in relation to problem drinking in nondependent alcohol drinkers.
2-1	209-213	Here	_
2-2	214-216	we	_
2-3	217-225	examined	_
2-4	226-239	error-related	_
2-5	240-250	activities	_
2-6	251-253	in	_
2-7	254-262	relation	_
2-8	263-265	to	_
2-9	266-273	problem	_
2-10	274-282	drinking	_
2-11	283-285	in	_
2-12	286-298	nondependent	_
2-13	299-306	alcohol	_
2-14	307-315	drinkers	_
2-15	316-317	.	_

Text=In particular, we investigated sex differences and whether altered error responses are related to post-error behavioral control.
3-1	318-320	In	_
3-2	321-331	particular	_
3-3	332-333	,	_
3-4	334-336	we	_
3-5	337-349	investigated	_
3-6	350-353	sex	_
3-7	354-365	differences	_
3-8	366-369	and	_
3-9	370-377	whether	_
3-10	378-385	altered	_
3-11	386-391	error	_
3-12	392-401	responses	_
3-13	402-405	are	_
3-14	406-413	related	_
3-15	414-416	to	_
3-16	417-427	post-error	_
3-17	428-438	behavioral	_
3-18	439-446	control	_
3-19	447-448	.	_

Text=Methods A sample of 145 non-dependent drinkers (77 women) performed the stop signal task during fMRI.
4-1	449-456	Methods	_
4-2	457-458	A	_
4-3	459-465	sample	_
4-4	466-468	of	_
4-5	469-472	145	_
4-6	473-486	non-dependent	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
4-7	487-495	drinkers	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
4-8	496-497	(	_
4-9	498-500	77	_
4-10	501-506	women	_
4-11	507-508	)	_
4-12	509-518	performed	_
4-13	519-522	the	_
4-14	523-527	stop	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
4-15	528-534	signal	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
4-16	535-539	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
4-17	540-546	during	_
4-18	547-551	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-19	552-553	.	_

Text=Imaging data were processed and modeled using statistical parametric mapping.
5-1	554-561	Imaging	_
5-2	562-566	data	_
5-3	567-571	were	_
5-4	572-581	processed	_
5-5	582-585	and	_
5-6	586-593	modeled	_
5-7	594-599	using	_
5-8	600-611	statistical	_
5-9	612-622	parametric	_
5-10	623-630	mapping	_
5-11	631-632	.	_

Text=Independent sample t-test and linear regression were employed to examine sex differences in error response and relationship between error response and problem drinking.
6-1	633-644	Independent	_
6-2	645-651	sample	_
6-3	652-658	t-test	_
6-4	659-662	and	_
6-5	663-669	linear	_
6-6	670-680	regression	_
6-7	681-685	were	_
6-8	686-694	employed	_
6-9	695-697	to	_
6-10	698-705	examine	_
6-11	706-709	sex	_
6-12	710-721	differences	_
6-13	722-724	in	_
6-14	725-730	error	_
6-15	731-739	response	_
6-16	740-743	and	_
6-17	744-756	relationship	_
6-18	757-764	between	_
6-19	765-770	error	_
6-20	771-779	response	_
6-21	780-783	and	_
6-22	784-791	problem	_
6-23	792-800	drinking	_
6-24	801-802	.	_

Text=Results Compared to men, women showed greater error-related (stop error> go success) activations in bilateral thalamus, right middle/superior temporal cortex and bilateral dorsal anterior cingulate cortex.
7-1	803-810	Results	_
7-2	811-819	Compared	_
7-3	820-822	to	_
7-4	823-826	men	_
7-5	827-828	,	_
7-6	829-834	women	_
7-7	835-841	showed	_
7-8	842-849	greater	_
7-9	850-863	error-related	_
7-10	864-865	(	_
7-11	866-870	stop	_
7-12	871-876	error	_
7-13	877-878	>	_
7-14	879-881	go	_
7-15	882-889	success	_
7-16	890-891	)	_
7-17	892-903	activations	_
7-18	904-906	in	_
7-19	907-916	bilateral	_
7-20	917-925	thalamus	_
7-21	926-927	,	_
7-22	928-933	right	_
7-23	934-949	middle/superior	_
7-24	950-958	temporal	_
7-25	959-965	cortex	_
7-26	966-969	and	_
7-27	970-979	bilateral	_
7-28	980-986	dorsal	_
7-29	987-995	anterior	_
7-30	996-1005	cingulate	_
7-31	1006-1012	cortex	_
7-32	1013-1014	.	_

Text=In whole-brain linear regression of error responses against the Alcohol Use Disorder Identification Test (AUDIT) score, a wide swath of cortical and subcortical regions, including the thalamus, showed decreased activation in association with problem drinking in women but not in men.
8-1	1015-1017	In	_
8-2	1018-1029	whole-brain	_
8-3	1030-1036	linear	_
8-4	1037-1047	regression	_
8-5	1048-1050	of	_
8-6	1051-1056	error	_
8-7	1057-1066	responses	_
8-8	1067-1074	against	_
8-9	1075-1078	the	_
8-10	1079-1086	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
8-11	1087-1090	Use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
8-12	1091-1099	Disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
8-13	1100-1114	Identification	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
8-14	1115-1119	Test	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
8-15	1120-1121	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
8-16	1122-1127	AUDIT	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
8-17	1128-1129	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
8-18	1130-1135	score	_
8-19	1136-1137	,	_
8-20	1138-1139	a	_
8-21	1140-1144	wide	_
8-22	1145-1150	swath	_
8-23	1151-1153	of	_
8-24	1154-1162	cortical	_
8-25	1163-1166	and	_
8-26	1167-1178	subcortical	_
8-27	1179-1186	regions	_
8-28	1187-1188	,	_
8-29	1189-1198	including	_
8-30	1199-1202	the	_
8-31	1203-1211	thalamus	_
8-32	1212-1213	,	_
8-33	1214-1220	showed	_
8-34	1221-1230	decreased	_
8-35	1231-1241	activation	_
8-36	1242-1244	in	_
8-37	1245-1256	association	_
8-38	1257-1261	with	_
8-39	1262-1269	problem	_
8-40	1270-1278	drinking	_
8-41	1279-1281	in	_
8-42	1282-1287	women	_
8-43	1288-1291	but	_
8-44	1292-1295	not	_
8-45	1296-1298	in	_
8-46	1299-1302	men	_
8-47	1303-1304	.	_

Text=However, men and women were not different in the extent of post-error slowing (PES) and decreased thalamic error response in association with problem drinking was not related to the extent of PES in women.
9-1	1305-1312	However	_
9-2	1313-1314	,	_
9-3	1315-1318	men	_
9-4	1319-1322	and	_
9-5	1323-1328	women	_
9-6	1329-1333	were	_
9-7	1334-1337	not	_
9-8	1338-1347	different	_
9-9	1348-1350	in	_
9-10	1351-1354	the	_
9-11	1355-1361	extent	_
9-12	1362-1364	of	_
9-13	1365-1375	post-error	_
9-14	1376-1383	slowing	_
9-15	1384-1385	(	_
9-16	1386-1389	PES	_
9-17	1390-1391	)	_
9-18	1392-1395	and	_
9-19	1396-1405	decreased	_
9-20	1406-1414	thalamic	_
9-21	1415-1420	error	_
9-22	1421-1429	response	_
9-23	1430-1432	in	_
9-24	1433-1444	association	_
9-25	1445-1449	with	_
9-26	1450-1457	problem	_
9-27	1458-1466	drinking	_
9-28	1467-1470	was	_
9-29	1471-1474	not	_
9-30	1475-1482	related	_
9-31	1483-1485	to	_
9-32	1486-1489	the	_
9-33	1490-1496	extent	_
9-34	1497-1499	of	_
9-35	1500-1503	PES	_
9-36	1504-1506	in	_
9-37	1507-1512	women	_
9-38	1513-1514	.	_

Text=Conclusions The results suggest sex differences in error-related activations with heavier drinking associated with reduced error activations in women but not in men.
10-1	1515-1526	Conclusions	_
10-2	1527-1530	The	_
10-3	1531-1538	results	_
10-4	1539-1546	suggest	_
10-5	1547-1550	sex	_
10-6	1551-1562	differences	_
10-7	1563-1565	in	_
10-8	1566-1579	error-related	_
10-9	1580-1591	activations	_
10-10	1592-1596	with	_
10-11	1597-1604	heavier	_
10-12	1605-1613	drinking	_
10-13	1614-1624	associated	_
10-14	1625-1629	with	_
10-15	1630-1637	reduced	_
10-16	1638-1643	error	_
10-17	1644-1655	activations	_
10-18	1656-1658	in	_
10-19	1659-1664	women	_
10-20	1665-1668	but	_
10-21	1669-1672	not	_
10-22	1673-1675	in	_
10-23	1676-1679	men	_
10-24	1680-1681	.	_

Text=These differences in cerebral activations may reflect higher physiological arousal in response to errors and greater vulnerability of saliency-related arousal response to problem drinking in female as compared to male social drinkers.
11-1	1682-1687	These	_
11-2	1688-1699	differences	_
11-3	1700-1702	in	_
11-4	1703-1711	cerebral	_
11-5	1712-1723	activations	_
11-6	1724-1727	may	_
11-7	1728-1735	reflect	_
11-8	1736-1742	higher	_
11-9	1743-1756	physiological	_
11-10	1757-1764	arousal	_
11-11	1765-1767	in	_
11-12	1768-1776	response	_
11-13	1777-1779	to	_
11-14	1780-1786	errors	_
11-15	1787-1790	and	_
11-16	1791-1798	greater	_
11-17	1799-1812	vulnerability	_
11-18	1813-1815	of	_
11-19	1816-1832	saliency-related	_
11-20	1833-1840	arousal	_
11-21	1841-1849	response	_
11-22	1850-1852	to	_
11-23	1853-1860	problem	_
11-24	1861-1869	drinking	_
11-25	1870-1872	in	_
11-26	1873-1879	female	_
11-27	1880-1882	as	_
11-28	1883-1891	compared	_
11-29	1892-1894	to	_
11-30	1895-1899	male	_
11-31	1900-1906	social	_
11-32	1907-1915	drinkers	_
11-33	1916-1917	.	_

Text=2.
12-1	1918-1919	2	_
12-2	1920-1921	.	_

Text=Methods 2.1 Subjects, Informed Consent, and Assessment Study participants were recruited with newspaper and radio advertisements as well as flyers posted in the greater New Haven area.
13-1	1922-1929	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
13-2	1930-1933	2.1	_
13-3	1934-1942	Subjects	_
13-4	1943-1944	,	_
13-5	1945-1953	Informed	_
13-6	1954-1961	Consent	_
13-7	1962-1963	,	_
13-8	1964-1967	and	_
13-9	1968-1978	Assessment	_
13-10	1979-1984	Study	_
13-11	1985-1997	participants	_
13-12	1998-2002	were	_
13-13	2003-2012	recruited	_
13-14	2013-2017	with	_
13-15	2018-2027	newspaper	_
13-16	2028-2031	and	_
13-17	2032-2037	radio	_
13-18	2038-2052	advertisements	_
13-19	2053-2055	as	_
13-20	2056-2060	well	_
13-21	2061-2063	as	_
13-22	2064-2070	flyers	_
13-23	2071-2077	posted	_
13-24	2078-2080	in	_
13-25	2081-2084	the	_
13-26	2085-2092	greater	_
13-27	2093-2096	New	_
13-28	2097-2102	Haven	_
13-29	2103-2107	area	_
13-30	2108-2109	.	_

Text=All participants were free of major medical illness, past or present neurological and psychiatric illnesses including substance use disorders (SCID-I for DSM-IV), denied current use of illicit substance, and showed negative urine toxicology tests for stimulants, opioids, marijuana, and benzodiazepines at the time of MRI.
14-1	2110-2113	All	_
14-2	2114-2126	participants	_
14-3	2127-2131	were	_
14-4	2132-2136	free	_
14-5	2137-2139	of	_
14-6	2140-2145	major	_
14-7	2146-2153	medical	_
14-8	2154-2161	illness	_
14-9	2162-2163	,	_
14-10	2164-2168	past	_
14-11	2169-2171	or	_
14-12	2172-2179	present	_
14-13	2180-2192	neurological	_
14-14	2193-2196	and	_
14-15	2197-2208	psychiatric	_
14-16	2209-2218	illnesses	_
14-17	2219-2228	including	_
14-18	2229-2238	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
14-19	2239-2242	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
14-20	2243-2252	disorders	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
14-21	2253-2254	(	_
14-22	2255-2261	SCID-I	_
14-23	2262-2265	for	_
14-24	2266-2272	DSM-IV	_
14-25	2273-2274	)	_
14-26	2275-2276	,	_
14-27	2277-2283	denied	_
14-28	2284-2291	current	_
14-29	2292-2295	use	_
14-30	2296-2298	of	_
14-31	2299-2306	illicit	_
14-32	2307-2316	substance	_
14-33	2317-2318	,	_
14-34	2319-2322	and	_
14-35	2323-2329	showed	_
14-36	2330-2338	negative	_
14-37	2339-2344	urine	_
14-38	2345-2355	toxicology	_
14-39	2356-2361	tests	_
14-40	2362-2365	for	_
14-41	2366-2376	stimulants	_
14-42	2377-2378	,	_
14-43	2379-2386	opioids	_
14-44	2387-2388	,	_
14-45	2389-2398	marijuana	_
14-46	2399-2400	,	_
14-47	2401-2404	and	_
14-48	2405-2420	benzodiazepines	_
14-49	2421-2423	at	_
14-50	2424-2427	the	_
14-51	2428-2432	time	_
14-52	2433-2435	of	_
14-53	2436-2439	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
14-54	2440-2441	.	_

Text=Individuals who were using any psychotropic medications were not invited to participate in the study.
15-1	2442-2453	Individuals	_
15-2	2454-2457	who	_
15-3	2458-2462	were	_
15-4	2463-2468	using	_
15-5	2469-2472	any	_
15-6	2473-2485	psychotropic	_
15-7	2486-2497	medications	_
15-8	2498-2502	were	_
15-9	2503-2506	not	_
15-10	2507-2514	invited	_
15-11	2515-2517	to	_
15-12	2518-2529	participate	_
15-13	2530-2532	in	_
15-14	2533-2536	the	_
15-15	2537-2542	study	_
15-16	2543-2544	.	_

Text=Pregnant or lactating women were also excluded.
16-1	2545-2553	Pregnant	_
16-2	2554-2556	or	_
16-3	2557-2566	lactating	_
16-4	2567-2572	women	_
16-5	2573-2577	were	_
16-6	2578-2582	also	_
16-7	2583-2591	excluded	_
16-8	2592-2593	.	_

Text=Participants were further required to be free of MRI-contraindications per Yale Magnetic Resonance Research Center's safety guidelines.
17-1	2594-2606	Participants	_
17-2	2607-2611	were	_
17-3	2612-2619	further	_
17-4	2620-2628	required	_
17-5	2629-2631	to	_
17-6	2632-2634	be	_
17-7	2635-2639	free	_
17-8	2640-2642	of	_
17-9	2643-2664	MRI-contraindications	_
17-10	2665-2668	per	_
17-11	2669-2673	Yale	_
17-12	2674-2682	Magnetic	_
17-13	2683-2692	Resonance	_
17-14	2693-2701	Research	_
17-15	2702-2708	Center	_
17-16	2709-2711	's	_
17-17	2712-2718	safety	_
17-18	2719-2729	guidelines	_
17-19	2730-2731	.	_

Text=One hundred and forty-five social drinkers (77 women; age 31 ± 13 years; all right-handed) were included in this study.
18-1	2732-2735	One	_
18-2	2736-2743	hundred	_
18-3	2744-2747	and	_
18-4	2748-2758	forty-five	_
18-5	2759-2765	social	http://maven.renci.org/NeuroBridge/neurobridge#TheSocialFunctionQuestionnaire
18-6	2766-2774	drinkers	http://maven.renci.org/NeuroBridge/neurobridge#TheSocialFunctionQuestionnaire
18-7	2775-2776	(	_
18-8	2777-2779	77	_
18-9	2780-2785	women	_
18-10	2786-2787	;	_
18-11	2788-2791	age	_
18-12	2792-2794	31	_
18-13	2795-2796	±	_
18-14	2797-2799	13	_
18-15	2800-2805	years	_
18-16	2806-2807	;	_
18-17	2808-2811	all	_
18-18	2812-2824	right-handed	_
18-19	2825-2826	)	_
18-20	2827-2831	were	_
18-21	2832-2840	included	_
18-22	2841-2843	in	_
18-23	2844-2848	this	_
18-24	2849-2854	study	_
18-25	2855-2856	.	_

Text=This cohort is a subsample of the 158 (86 women) social drinkers reported in our recent work, where 13 subjects participated in fMRI of a different behavioral task.
19-1	2857-2861	This	_
19-2	2862-2868	cohort	_
19-3	2869-2871	is	_
19-4	2872-2873	a	_
19-5	2874-2883	subsample	_
19-6	2884-2886	of	_
19-7	2887-2890	the	_
19-8	2891-2894	158	_
19-9	2895-2896	(	_
19-10	2897-2899	86	_
19-11	2900-2905	women	_
19-12	2906-2907	)	_
19-13	2908-2914	social	http://maven.renci.org/NeuroBridge/neurobridge#TheSocialFunctionQuestionnaire
19-14	2915-2923	drinkers	http://maven.renci.org/NeuroBridge/neurobridge#TheSocialFunctionQuestionnaire
19-15	2924-2932	reported	_
19-16	2933-2935	in	_
19-17	2936-2939	our	_
19-18	2940-2946	recent	_
19-19	2947-2951	work	_
19-20	2952-2953	,	_
19-21	2954-2959	where	_
19-22	2960-2962	13	_
19-23	2963-2971	subjects	_
19-24	2972-2984	participated	_
19-25	2985-2987	in	_
19-26	2988-2992	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
19-27	2993-2995	of	_
19-28	2996-2997	a	_
19-29	2998-3007	different	_
19-30	3008-3018	behavioral	_
19-31	3019-3023	task	_
19-32	3024-3025	.	_

Text=All participants completed questionnaires regarding alcohol use over the past year, including average number of days of drinking and average number of drinks consumed per occasion, framed on a monthly basis, as well as the Alcohol Use Disorders Identification Test (AUDIT).
20-1	3026-3029	All	_
20-2	3030-3042	participants	_
20-3	3043-3052	completed	_
20-4	3053-3067	questionnaires	_
20-5	3068-3077	regarding	_
20-6	3078-3085	alcohol	_
20-7	3086-3089	use	_
20-8	3090-3094	over	_
20-9	3095-3098	the	_
20-10	3099-3103	past	_
20-11	3104-3108	year	_
20-12	3109-3110	,	_
20-13	3111-3120	including	_
20-14	3121-3128	average	_
20-15	3129-3135	number	_
20-16	3136-3138	of	_
20-17	3139-3143	days	_
20-18	3144-3146	of	_
20-19	3147-3155	drinking	_
20-20	3156-3159	and	_
20-21	3160-3167	average	_
20-22	3168-3174	number	_
20-23	3175-3177	of	_
20-24	3178-3184	drinks	_
20-25	3185-3193	consumed	_
20-26	3194-3197	per	_
20-27	3198-3206	occasion	_
20-28	3207-3208	,	_
20-29	3209-3215	framed	_
20-30	3216-3218	on	_
20-31	3219-3220	a	_
20-32	3221-3228	monthly	_
20-33	3229-3234	basis	_
20-34	3235-3236	,	_
20-35	3237-3239	as	_
20-36	3240-3244	well	_
20-37	3245-3247	as	_
20-38	3248-3251	the	_
20-39	3252-3259	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
20-40	3260-3263	Use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
20-41	3264-3273	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
20-42	3274-3288	Identification	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
20-43	3289-3293	Test	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
20-44	3294-3295	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
20-45	3296-3301	AUDIT	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
20-46	3302-3303	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
20-47	3304-3305	.	_

Text=AUDIT score was calculated by summing subscores of ten self-report questions regarding level of alcohol use, alcohol-related problems, and concern expressed by others for one's drinking behavior.
21-1	3306-3311	AUDIT	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
21-2	3312-3317	score	_
21-3	3318-3321	was	_
21-4	3322-3332	calculated	_
21-5	3333-3335	by	_
21-6	3336-3343	summing	_
21-7	3344-3353	subscores	_
21-8	3354-3356	of	_
21-9	3357-3360	ten	_
21-10	3361-3372	self-report	_
21-11	3373-3382	questions	_
21-12	3383-3392	regarding	_
21-13	3393-3398	level	_
21-14	3399-3401	of	_
21-15	3402-3409	alcohol	_
21-16	3410-3413	use	_
21-17	3414-3415	,	_
21-18	3416-3431	alcohol-related	_
21-19	3432-3440	problems	_
21-20	3441-3442	,	_
21-21	3443-3446	and	_
21-22	3447-3454	concern	_
21-23	3455-3464	expressed	_
21-24	3465-3467	by	_
21-25	3468-3474	others	_
21-26	3475-3478	for	_
21-27	3479-3482	one	_
21-28	3483-3485	's	_
21-29	3486-3494	drinking	_
21-30	3495-3503	behavior	_
21-31	3504-3505	.	_

Text=Each question receives a score ranging from 0 to 4, with higher numbers corresponding to a greater level of risk for having or developing an alcohol use disorder.
22-1	3506-3510	Each	_
22-2	3511-3519	question	_
22-3	3520-3528	receives	_
22-4	3529-3530	a	_
22-5	3531-3536	score	_
22-6	3537-3544	ranging	_
22-7	3545-3549	from	_
22-8	3550-3551	0	_
22-9	3552-3554	to	_
22-10	3555-3556	4	_
22-11	3557-3558	,	_
22-12	3559-3563	with	_
22-13	3564-3570	higher	_
22-14	3571-3578	numbers	_
22-15	3579-3592	corresponding	_
22-16	3593-3595	to	_
22-17	3596-3597	a	_
22-18	3598-3605	greater	_
22-19	3606-3611	level	_
22-20	3612-3614	of	_
22-21	3615-3619	risk	_
22-22	3620-3623	for	_
22-23	3624-3630	having	_
22-24	3631-3633	or	_
22-25	3634-3644	developing	_
22-26	3645-3647	an	_
22-27	3648-3655	alcohol	_
22-28	3656-3659	use	_
22-29	3660-3668	disorder	_
22-30	3669-3670	.	_

Text=The mean (± SD) AUDIT score was 5.1 (± 4.2) across all subjects, in a range typical of non-dependent drinkers and significantly lower than those reported for alcohol dependent individuals.
23-1	3671-3674	The	_
23-2	3675-3679	mean	_
23-3	3680-3681	(	_
23-4	3682-3683	±	_
23-5	3684-3686	SD	_
23-6	3687-3688	)	_
23-7	3689-3694	AUDIT	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
23-8	3695-3700	score	_
23-9	3701-3704	was	_
23-10	3705-3708	5.1	_
23-11	3709-3710	(	_
23-12	3711-3712	±	_
23-13	3713-3716	4.2	_
23-14	3717-3718	)	_
23-15	3719-3725	across	_
23-16	3726-3729	all	_
23-17	3730-3738	subjects	_
23-18	3739-3740	,	_
23-19	3741-3743	in	_
23-20	3744-3745	a	_
23-21	3746-3751	range	_
23-22	3752-3759	typical	_
23-23	3760-3762	of	_
23-24	3763-3776	non-dependent	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
23-25	3777-3785	drinkers	_
23-26	3786-3789	and	_
23-27	3790-3803	significantly	_
23-28	3804-3809	lower	_
23-29	3810-3814	than	_
23-30	3815-3820	those	_
23-31	3821-3829	reported	_
23-32	3830-3833	for	_
23-33	3834-3841	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
23-34	3842-3851	dependent	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
23-35	3852-3863	individuals	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
23-36	3864-3865	.	_

Text=Participants were also assessed with the Barratt Impulsivity Scale (BIS-11) and Alcohol Expectancy Questionnaire (AEQ-3).
24-1	3866-3878	Participants	_
24-2	3879-3883	were	_
24-3	3884-3888	also	_
24-4	3889-3897	assessed	_
24-5	3898-3902	with	_
24-6	3903-3906	the	_
24-7	3907-3914	Barratt	http://maven.renci.org/NeuroBridge/neurobridge#ImpulsivityScale
24-8	3915-3926	Impulsivity	http://maven.renci.org/NeuroBridge/neurobridge#ImpulsivityScale
24-9	3927-3932	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ImpulsivityScale
24-10	3933-3934	(	http://maven.renci.org/NeuroBridge/neurobridge#ImpulsivityScale
24-11	3935-3941	BIS-11	_
24-12	3942-3943	)	_
24-13	3944-3947	and	_
24-14	3948-3955	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
24-15	3956-3966	Expectancy	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
24-16	3967-3980	Questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
24-17	3981-3982	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
24-18	3983-3988	AEQ-3	_
24-19	3989-3990	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
24-20	3991-3992	.	_

Text=BIS-11 is a 30-item self-report questionnaire designed to measure impulsivity.
25-1	3993-3999	BIS-11	_
25-2	4000-4002	is	_
25-3	4003-4004	a	_
25-4	4005-4012	30-item	_
25-5	4013-4024	self-report	_
25-6	4025-4038	questionnaire	_
25-7	4039-4047	designed	_
25-8	4048-4050	to	_
25-9	4051-4058	measure	_
25-10	4059-4070	impulsivity	_
25-11	4071-4072	.	_

Text=All items are scored on a 4-point scale (1 = rarely/never; 2 = occasionally; 3 = often; 4 = almost always/always).
26-1	4073-4076	All	_
26-2	4077-4082	items	_
26-3	4083-4086	are	_
26-4	4087-4093	scored	_
26-5	4094-4096	on	_
26-6	4097-4098	a	_
26-7	4099-4106	4-point	_
26-8	4107-4112	scale	_
26-9	4113-4114	(	_
26-10	4115-4116	1	_
26-11	4117-4118	=	_
26-12	4119-4131	rarely/never	_
26-13	4132-4133	;	_
26-14	4134-4135	2	_
26-15	4136-4137	=	_
26-16	4138-4150	occasionally	_
26-17	4151-4152	;	_
26-18	4153-4154	3	_
26-19	4155-4156	=	_
26-20	4157-4162	often	_
26-21	4163-4164	;	_
26-22	4165-4166	4	_
26-23	4167-4168	=	_
26-24	4169-4175	almost	_
26-25	4176-4189	always/always	_
26-26	4190-4191	)	_
26-27	4192-4193	.	_

Text=The total score thus ranges from 30 to 120, with a higher score indicating higher impulsivity.
27-1	4194-4197	The	_
27-2	4198-4203	total	_
27-3	4204-4209	score	_
27-4	4210-4214	thus	_
27-5	4215-4221	ranges	_
27-6	4222-4226	from	_
27-7	4227-4229	30	_
27-8	4230-4232	to	_
27-9	4233-4236	120	_
27-10	4237-4238	,	_
27-11	4239-4243	with	_
27-12	4244-4245	a	_
27-13	4246-4252	higher	_
27-14	4253-4258	score	_
27-15	4259-4269	indicating	_
27-16	4270-4276	higher	_
27-17	4277-4288	impulsivity	_
27-18	4289-4290	.	_

Text=Eleven of the 30 items are reverse scored to avoid response bias.
28-1	4291-4297	Eleven	_
28-2	4298-4300	of	_
28-3	4301-4304	the	_
28-4	4305-4307	30	_
28-5	4308-4313	items	_
28-6	4314-4317	are	_
28-7	4318-4325	reverse	_
28-8	4326-4332	scored	_
28-9	4333-4335	to	_
28-10	4336-4341	avoid	_
28-11	4342-4350	response	_
28-12	4351-4355	bias	_
28-13	4356-4357	.	_

Text=The AEQ-3 consisted of 40 items to address both positive (6 subscales) and negative (2 subscales) alcohol expectancy, confirmed by factor analysis and invariant across sex and race.
29-1	4358-4361	The	_
29-2	4362-4367	AEQ-3	_
29-3	4368-4377	consisted	_
29-4	4378-4380	of	_
29-5	4381-4383	40	_
29-6	4384-4389	items	_
29-7	4390-4392	to	_
29-8	4393-4400	address	_
29-9	4401-4405	both	_
29-10	4406-4414	positive	_
29-11	4415-4416	(	_
29-12	4417-4418	6	_
29-13	4419-4428	subscales	_
29-14	4429-4430	)	_
29-15	4431-4434	and	_
29-16	4435-4443	negative	_
29-17	4444-4445	(	_
29-18	4446-4447	2	_
29-19	4448-4457	subscales	_
29-20	4458-4459	)	_
29-21	4460-4467	alcohol	_
29-22	4468-4478	expectancy	_
29-23	4479-4480	,	_
29-24	4481-4490	confirmed	_
29-25	4491-4493	by	_
29-26	4494-4500	factor	_
29-27	4501-4509	analysis	_
29-28	4510-4513	and	_
29-29	4514-4523	invariant	_
29-30	4524-4530	across	_
29-31	4531-4534	sex	_
29-32	4535-4538	and	_
29-33	4539-4543	race	_
29-34	4544-4545	.	_

Text=Each subscale contains 4 to 6 statements that can be endorsed on a six-point scale, from “ disagree strongly ” to “ agree strongly ”.
30-1	4546-4550	Each	_
30-2	4551-4559	subscale	_
30-3	4560-4568	contains	_
30-4	4569-4570	4	_
30-5	4571-4573	to	_
30-6	4574-4575	6	_
30-7	4576-4586	statements	_
30-8	4587-4591	that	_
30-9	4592-4595	can	_
30-10	4596-4598	be	_
30-11	4599-4607	endorsed	_
30-12	4608-4610	on	_
30-13	4611-4612	a	_
30-14	4613-4622	six-point	_
30-15	4623-4628	scale	_
30-16	4629-4630	,	_
30-17	4631-4635	from	_
30-18	4636-4637	“	_
30-19	4638-4646	disagree	_
30-20	4647-4655	strongly	_
30-21	4656-4657	”	_
30-22	4658-4660	to	_
30-23	4661-4662	“	_
30-24	4663-4668	agree	_
30-25	4669-4677	strongly	_
30-26	4678-4679	”	_
30-27	4680-4681	.	_

Text=Despite the 8 factors identified and confirmed with factor analysis, ratings on the 8 factors are highly correlated (George et al, 1995).
31-1	4682-4689	Despite	_
31-2	4690-4693	the	_
31-3	4694-4695	8	_
31-4	4696-4703	factors	_
31-5	4704-4714	identified	_
31-6	4715-4718	and	_
31-7	4719-4728	confirmed	_
31-8	4729-4733	with	_
31-9	4734-4740	factor	_
31-10	4741-4749	analysis	_
31-11	4750-4751	,	_
31-12	4752-4759	ratings	_
31-13	4760-4762	on	_
31-14	4763-4766	the	_
31-15	4767-4768	8	_
31-16	4769-4776	factors	_
31-17	4777-4780	are	_
31-18	4781-4787	highly	_
31-19	4788-4798	correlated	_
31-20	4799-4800	(	_
31-21	4801-4807	George	_
31-22	4808-4810	et	_
31-23	4811-4813	al	_
31-24	4814-4815	,	_
31-25	4816-4820	1995	_
31-26	4821-4822	)	_
31-27	4823-4824	.	_

Text=Thus, the authors acknowledged that the discriminant validity among the 8 subscores was at best moderate.
32-1	4825-4829	Thus	_
32-2	4830-4831	,	_
32-3	4832-4835	the	_
32-4	4836-4843	authors	_
32-5	4844-4856	acknowledged	_
32-6	4857-4861	that	_
32-7	4862-4865	the	_
32-8	4866-4878	discriminant	_
32-9	4879-4887	validity	_
32-10	4888-4893	among	_
32-11	4894-4897	the	_
32-12	4898-4899	8	_
32-13	4900-4909	subscores	_
32-14	4910-4913	was	_
32-15	4914-4916	at	_
32-16	4917-4921	best	_
32-17	4922-4930	moderate	_
32-18	4931-4932	.	_

Text=Here, we used the global positive subscore to represent alcohol expectancy.
33-1	4933-4937	Here	_
33-2	4938-4939	,	_
33-3	4940-4942	we	_
33-4	4943-4947	used	_
33-5	4948-4951	the	_
33-6	4952-4958	global	_
33-7	4959-4967	positive	_
33-8	4968-4976	subscore	_
33-9	4977-4979	to	_
33-10	4980-4989	represent	_
33-11	4990-4997	alcohol	_
33-12	4998-5008	expectancy	_
33-13	5009-5010	.	_

Text=A summary of demographic and clinical measures is presented in Table 1.
34-1	5011-5012	A	_
34-2	5013-5020	summary	_
34-3	5021-5023	of	_
34-4	5024-5035	demographic	_
34-5	5036-5039	and	_
34-6	5040-5048	clinical	_
34-7	5049-5057	measures	_
34-8	5058-5060	is	_
34-9	5061-5070	presented	_
34-10	5071-5073	in	_
34-11	5074-5079	Table	_
34-12	5080-5081	1	_
34-13	5082-5083	.	_

Text=All subjects signed a written informed consent, in accordance to a protocol approved by the Yale Human Investigation Committee, prior to the study.
35-1	5084-5087	All	_
35-2	5088-5096	subjects	_
35-3	5097-5103	signed	_
35-4	5104-5105	a	_
35-5	5106-5113	written	_
35-6	5114-5122	informed	_
35-7	5123-5130	consent	_
35-8	5131-5132	,	_
35-9	5133-5135	in	_
35-10	5136-5146	accordance	_
35-11	5147-5149	to	_
35-12	5150-5151	a	_
35-13	5152-5160	protocol	_
35-14	5161-5169	approved	_
35-15	5170-5172	by	_
35-16	5173-5176	the	_
35-17	5177-5181	Yale	_
35-18	5182-5187	Human	_
35-19	5188-5201	Investigation	_
35-20	5202-5211	Committee	_
35-21	5212-5213	,	_
35-22	5214-5219	prior	_
35-23	5220-5222	to	_
35-24	5223-5226	the	_
35-25	5227-5232	study	_
35-26	5233-5234	.	_

Text=2.2 Behavioral task We employed a simple reaction time task in this stop-signal paradigm.
36-1	5235-5238	2.2	_
36-2	5239-5249	Behavioral	_
36-3	5250-5254	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
36-4	5255-5257	We	_
36-5	5258-5266	employed	_
36-6	5267-5268	a	_
36-7	5269-5275	simple	_
36-8	5276-5284	reaction	http://maven.renci.org/NeuroBridge/neurobridge#PolymeraseChainReaction
36-9	5285-5289	time	http://maven.renci.org/NeuroBridge/neurobridge#PolymeraseChainReaction
36-10	5290-5294	task	http://maven.renci.org/NeuroBridge/neurobridge#PolymeraseChainReaction
36-11	5295-5297	in	_
36-12	5298-5302	this	_
36-13	5303-5314	stop-signal	_
36-14	5315-5323	paradigm	http://maven.renci.org/NeuroBridge/neurobridge#SternbergItemRecognitionParadigmTask
36-15	5324-5325	.	_

Text=There were two trial types: “ go ” and “ stop, ” randomly intermixed in presentation each with a probability of 0.75 and 0.25, and with an inter-trial interval of 2 s. A small dot appeared on the screen to engage attention at the beginning of a go trial.
37-1	5326-5331	There	_
37-2	5332-5336	were	_
37-3	5337-5340	two	_
37-4	5341-5346	trial	_
37-5	5347-5352	types	_
37-6	5353-5354	:	_
37-7	5355-5356	“	_
37-8	5357-5359	go	_
37-9	5360-5361	”	_
37-10	5362-5365	and	_
37-11	5366-5367	“	_
37-12	5368-5372	stop	_
37-13	5373-5374	,	_
37-14	5375-5376	”	_
37-15	5377-5385	randomly	_
37-16	5386-5396	intermixed	_
37-17	5397-5399	in	_
37-18	5400-5412	presentation	_
37-19	5413-5417	each	_
37-20	5418-5422	with	_
37-21	5423-5424	a	_
37-22	5425-5436	probability	_
37-23	5437-5439	of	_
37-24	5440-5444	0.75	_
37-25	5445-5448	and	_
37-26	5449-5453	0.25	_
37-27	5454-5455	,	_
37-28	5456-5459	and	_
37-29	5460-5464	with	_
37-30	5465-5467	an	_
37-31	5468-5479	inter-trial	_
37-32	5480-5488	interval	_
37-33	5489-5491	of	_
37-34	5492-5493	2	_
37-35	5494-5496	s.	_
37-36	5497-5498	A	_
37-37	5499-5504	small	_
37-38	5505-5508	dot	_
37-39	5509-5517	appeared	_
37-40	5518-5520	on	_
37-41	5521-5524	the	_
37-42	5525-5531	screen	_
37-43	5532-5534	to	_
37-44	5535-5541	engage	_
37-45	5542-5551	attention	_
37-46	5552-5554	at	_
37-47	5555-5558	the	_
37-48	5559-5568	beginning	_
37-49	5569-5571	of	_
37-50	5572-5573	a	_
37-51	5574-5576	go	_
37-52	5577-5582	trial	_
37-53	5583-5584	.	_

Text=After a randomized time interval between 1 and 5 s, drawn from a uniform distribution, the dot turned into a circle (the “ go ” signal), prompting the subjects to quickly press a button.
38-1	5585-5590	After	_
38-2	5591-5592	a	_
38-3	5593-5603	randomized	_
38-4	5604-5608	time	_
38-5	5609-5617	interval	_
38-6	5618-5625	between	_
38-7	5626-5627	1	_
38-8	5628-5631	and	_
38-9	5632-5633	5	_
38-10	5634-5635	s	_
38-11	5636-5637	,	_
38-12	5638-5643	drawn	_
38-13	5644-5648	from	_
38-14	5649-5650	a	_
38-15	5651-5658	uniform	_
38-16	5659-5671	distribution	_
38-17	5672-5673	,	_
38-18	5674-5677	the	_
38-19	5678-5681	dot	_
38-20	5682-5688	turned	_
38-21	5689-5693	into	_
38-22	5694-5695	a	_
38-23	5696-5702	circle	_
38-24	5703-5704	(	_
38-25	5705-5708	the	_
38-26	5709-5710	“	_
38-27	5711-5713	go	_
38-28	5714-5715	”	_
38-29	5716-5722	signal	_
38-30	5723-5724	)	_
38-31	5725-5726	,	_
38-32	5727-5736	prompting	_
38-33	5737-5740	the	_
38-34	5741-5749	subjects	_
38-35	5750-5752	to	_
38-36	5753-5760	quickly	_
38-37	5761-5766	press	_
38-38	5767-5768	a	_
38-39	5769-5775	button	_
38-40	5776-5777	.	_

Text=The circle vanished at a button press or after 1 s has elapsed, whichever came first, and the trial terminated.
39-1	5778-5781	The	_
39-2	5782-5788	circle	_
39-3	5789-5797	vanished	_
39-4	5798-5800	at	_
39-5	5801-5802	a	_
39-6	5803-5809	button	_
39-7	5810-5815	press	_
39-8	5816-5818	or	_
39-9	5819-5824	after	_
39-10	5825-5826	1	_
39-11	5827-5828	s	_
39-12	5829-5832	has	_
39-13	5833-5840	elapsed	_
39-14	5841-5842	,	_
39-15	5843-5852	whichever	_
39-16	5853-5857	came	_
39-17	5858-5863	first	_
39-18	5864-5865	,	_
39-19	5866-5869	and	_
39-20	5870-5873	the	_
39-21	5874-5879	trial	_
39-22	5880-5890	terminated	_
39-23	5891-5892	.	_

Text=A premature button press prior to the appearance of the circle also terminated the trial.
40-1	5893-5894	A	_
40-2	5895-5904	premature	_
40-3	5905-5911	button	_
40-4	5912-5917	press	_
40-5	5918-5923	prior	_
40-6	5924-5926	to	_
40-7	5927-5930	the	_
40-8	5931-5941	appearance	_
40-9	5942-5944	of	_
40-10	5945-5948	the	_
40-11	5949-5955	circle	_
40-12	5956-5960	also	_
40-13	5961-5971	terminated	_
40-14	5972-5975	the	_
40-15	5976-5981	trial	_
40-16	5982-5983	.	_

Text=In a stop trial, an additional “ X, ” the “ stop ” signal, appeared after and replaced the go signal, and instructed participants to withhold their response.
41-1	5984-5986	In	_
41-2	5987-5988	a	_
41-3	5989-5993	stop	_
41-4	5994-5999	trial	_
41-5	6000-6001	,	_
41-6	6002-6004	an	_
41-7	6005-6015	additional	_
41-8	6016-6017	“	_
41-9	6018-6019	X	_
41-10	6020-6021	,	_
41-11	6022-6023	”	_
41-12	6024-6027	the	_
41-13	6028-6029	“	_
41-14	6030-6034	stop	_
41-15	6035-6036	”	_
41-16	6037-6043	signal	_
41-17	6044-6045	,	_
41-18	6046-6054	appeared	_
41-19	6055-6060	after	_
41-20	6061-6064	and	_
41-21	6065-6073	replaced	_
41-22	6074-6077	the	_
41-23	6078-6080	go	_
41-24	6081-6087	signal	_
41-25	6088-6089	,	_
41-26	6090-6093	and	_
41-27	6094-6104	instructed	_
41-28	6105-6117	participants	_
41-29	6118-6120	to	_
41-30	6121-6129	withhold	_
41-31	6130-6135	their	_
41-32	6136-6144	response	_
41-33	6145-6146	.	_

Text=Similar to go trials, a stop trial terminated at button press or 1 s after the appearance of the stop signal.
42-1	6147-6154	Similar	_
42-2	6155-6157	to	_
42-3	6158-6160	go	_
42-4	6161-6167	trials	_
42-5	6168-6169	,	_
42-6	6170-6171	a	_
42-7	6172-6176	stop	_
42-8	6177-6182	trial	_
42-9	6183-6193	terminated	_
42-10	6194-6196	at	_
42-11	6197-6203	button	_
42-12	6204-6209	press	_
42-13	6210-6212	or	_
42-14	6213-6214	1	_
42-15	6215-6216	s	_
42-16	6217-6222	after	_
42-17	6223-6226	the	_
42-18	6227-6237	appearance	_
42-19	6238-6240	of	_
42-20	6241-6244	the	_
42-21	6245-6249	stop	_
42-22	6250-6256	signal	_
42-23	6257-6258	.	_

Text=Failure to withhold the response for the 1 s constituted a stop error.
43-1	6259-6266	Failure	_
43-2	6267-6269	to	_
43-3	6270-6278	withhold	_
43-4	6279-6282	the	_
43-5	6283-6291	response	_
43-6	6292-6295	for	_
43-7	6296-6299	the	_
43-8	6300-6301	1	_
43-9	6302-6303	s	_
43-10	6304-6315	constituted	_
43-11	6316-6317	a	_
43-12	6318-6322	stop	_
43-13	6323-6328	error	_
43-14	6329-6330	.	_

Text=The stop signal delay (SSD) – the time interval between go and stop signals – started at 200 ms and was adjusted according to a staircase procedure, increasing and decreasing by 67 ms each after a successful and failed stop.
44-1	6331-6334	The	_
44-2	6335-6339	stop	_
44-3	6340-6346	signal	_
44-4	6347-6352	delay	_
44-5	6353-6354	(	_
44-6	6355-6358	SSD	_
44-7	6359-6360	)	_
44-8	6361-6362	–	_
44-9	6363-6366	the	_
44-10	6367-6371	time	_
44-11	6372-6380	interval	_
44-12	6381-6388	between	_
44-13	6389-6391	go	_
44-14	6392-6395	and	_
44-15	6396-6400	stop	_
44-16	6401-6408	signals	_
44-17	6409-6410	–	_
44-18	6411-6418	started	_
44-19	6419-6421	at	_
44-20	6422-6425	200	_
44-21	6426-6428	ms	_
44-22	6429-6432	and	_
44-23	6433-6436	was	_
44-24	6437-6445	adjusted	_
44-25	6446-6455	according	_
44-26	6456-6458	to	_
44-27	6459-6460	a	_
44-28	6461-6470	staircase	_
44-29	6471-6480	procedure	_
44-30	6481-6482	,	_
44-31	6483-6493	increasing	_
44-32	6494-6497	and	_
44-33	6498-6508	decreasing	_
44-34	6509-6511	by	_
44-35	6512-6514	67	_
44-36	6515-6517	ms	_
44-37	6518-6522	each	_
44-38	6523-6528	after	_
44-39	6529-6530	a	_
44-40	6531-6541	successful	_
44-41	6542-6545	and	_
44-42	6546-6552	failed	_
44-43	6553-6557	stop	_
44-44	6558-6559	.	_

Text=Subjects were instructed to respond to the go signal quickly while keeping in mind that a stop signal could come up occasionally.
45-1	6560-6568	Subjects	_
45-2	6569-6573	were	_
45-3	6574-6584	instructed	_
45-4	6585-6587	to	_
45-5	6588-6595	respond	_
45-6	6596-6598	to	_
45-7	6599-6602	the	_
45-8	6603-6605	go	_
45-9	6606-6612	signal	_
45-10	6613-6620	quickly	_
45-11	6621-6626	while	_
45-12	6627-6634	keeping	_
45-13	6635-6637	in	_
45-14	6638-6642	mind	_
45-15	6643-6647	that	_
45-16	6648-6649	a	_
45-17	6650-6654	stop	_
45-18	6655-6661	signal	_
45-19	6662-6667	could	_
45-20	6668-6672	come	_
45-21	6673-6675	up	_
45-22	6676-6688	occasionally	_
45-23	6689-6690	.	_

Text=The staircase procedure ensures that subjects would succeed in withholding their response in approximately half of the stop trials.
46-1	6691-6694	The	_
46-2	6695-6704	staircase	_
46-3	6705-6714	procedure	_
46-4	6715-6722	ensures	_
46-5	6723-6727	that	_
46-6	6728-6736	subjects	_
46-7	6737-6742	would	_
46-8	6743-6750	succeed	_
46-9	6751-6753	in	_
46-10	6754-6765	withholding	_
46-11	6766-6771	their	_
46-12	6772-6780	response	_
46-13	6781-6783	in	_
46-14	6784-6797	approximately	_
46-15	6798-6802	half	_
46-16	6803-6805	of	_
46-17	6806-6809	the	_
46-18	6810-6814	stop	_
46-19	6815-6821	trials	_
46-20	6822-6823	.	_

Text=2.3 Analyses of behavioral performance in the stop signal task We computed a critical SSD that represents the time delay between go and stop signals that a subject would need to succeed in 50% of the stop trials.
47-1	6824-6827	2.3	_
47-2	6828-6836	Analyses	_
47-3	6837-6839	of	_
47-4	6840-6850	behavioral	_
47-5	6851-6862	performance	_
47-6	6863-6865	in	_
47-7	6866-6869	the	_
47-8	6870-6874	stop	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
47-9	6875-6881	signal	_
47-10	6882-6886	task	_
47-11	6887-6889	We	_
47-12	6890-6898	computed	_
47-13	6899-6900	a	_
47-14	6901-6909	critical	_
47-15	6910-6913	SSD	_
47-16	6914-6918	that	_
47-17	6919-6929	represents	_
47-18	6930-6933	the	_
47-19	6934-6938	time	_
47-20	6939-6944	delay	_
47-21	6945-6952	between	_
47-22	6953-6955	go	_
47-23	6956-6959	and	_
47-24	6960-6964	stop	_
47-25	6965-6972	signals	_
47-26	6973-6977	that	_
47-27	6978-6979	a	_
47-28	6980-6987	subject	_
47-29	6988-6993	would	_
47-30	6994-6998	need	_
47-31	6999-7001	to	_
47-32	7002-7009	succeed	_
47-33	7010-7012	in	_
47-34	7013-7015	50	_
47-35	7016-7017	%	_
47-36	7018-7020	of	_
47-37	7021-7024	the	_
47-38	7025-7029	stop	_
47-39	7030-7036	trials	_
47-40	7037-7038	.	_

Text=Specifically, SSDs across trials were grouped into runs, with each run defined as a monotonically increasing or decreasing series.
48-1	7039-7051	Specifically	_
48-2	7052-7053	,	_
48-3	7054-7058	SSDs	_
48-4	7059-7065	across	_
48-5	7066-7072	trials	_
48-6	7073-7077	were	_
48-7	7078-7085	grouped	_
48-8	7086-7090	into	_
48-9	7091-7095	runs	_
48-10	7096-7097	,	_
48-11	7098-7102	with	_
48-12	7103-7107	each	_
48-13	7108-7111	run	_
48-14	7112-7119	defined	_
48-15	7120-7122	as	_
48-16	7123-7124	a	_
48-17	7125-7138	monotonically	_
48-18	7139-7149	increasing	_
48-19	7150-7152	or	_
48-20	7153-7163	decreasing	_
48-21	7164-7170	series	_
48-22	7171-7172	.	_

Text=We derived a mid-run estimate by taking the median SSD of every second run.
49-1	7173-7175	We	_
49-2	7176-7183	derived	_
49-3	7184-7185	a	_
49-4	7186-7193	mid-run	_
49-5	7194-7202	estimate	_
49-6	7203-7205	by	_
49-7	7206-7212	taking	_
49-8	7213-7216	the	_
49-9	7217-7223	median	_
49-10	7224-7227	SSD	_
49-11	7228-7230	of	_
49-12	7231-7236	every	_
49-13	7237-7243	second	_
49-14	7244-7247	run	_
49-15	7248-7249	.	_

Text=The critical SSD was computed by taking the mean of all mid-run SSDs.
50-1	7250-7253	The	_
50-2	7254-7262	critical	_
50-3	7263-7266	SSD	_
50-4	7267-7270	was	_
50-5	7271-7279	computed	_
50-6	7280-7282	by	_
50-7	7283-7289	taking	_
50-8	7290-7293	the	_
50-9	7294-7298	mean	_
50-10	7299-7301	of	_
50-11	7302-7305	all	_
50-12	7306-7313	mid-run	_
50-13	7314-7318	SSDs	_
50-14	7319-7320	.	_

Text=It was reported that, except for experiments with a small number of trials (less than 30), the mid-run estimate was close to the maximum likelihood estimate of X50 (50% positive response; i.e., 50% stop success in the SST,).
51-1	7321-7323	It	_
51-2	7324-7327	was	_
51-3	7328-7336	reported	_
51-4	7337-7341	that	_
51-5	7342-7343	,	_
51-6	7344-7350	except	_
51-7	7351-7354	for	_
51-8	7355-7366	experiments	_
51-9	7367-7371	with	_
51-10	7372-7373	a	_
51-11	7374-7379	small	_
51-12	7380-7386	number	_
51-13	7387-7389	of	_
51-14	7390-7396	trials	_
51-15	7397-7398	(	_
51-16	7399-7403	less	_
51-17	7404-7408	than	_
51-18	7409-7411	30	_
51-19	7412-7413	)	_
51-20	7414-7415	,	_
51-21	7416-7419	the	_
51-22	7420-7427	mid-run	_
51-23	7428-7436	estimate	_
51-24	7437-7440	was	_
51-25	7441-7446	close	_
51-26	7447-7449	to	_
51-27	7450-7453	the	_
51-28	7454-7461	maximum	_
51-29	7462-7472	likelihood	_
51-30	7473-7481	estimate	_
51-31	7482-7484	of	_
51-32	7485-7488	X50	_
51-33	7489-7490	(	_
51-34	7491-7493	50	_
51-35	7494-7495	%	_
51-36	7496-7504	positive	_
51-37	7505-7513	response	_
51-38	7514-7515	;	_
51-39	7516-7520	i.e.	_
51-40	7521-7522	,	_
51-41	7523-7525	50	_
51-42	7526-7527	%	_
51-43	7528-7532	stop	_
51-44	7533-7540	success	_
51-45	7541-7543	in	_
51-46	7544-7547	the	_
51-47	7548-7551	SST	_
51-48	7552-7553	,	_
51-49	7554-7555	)	_
51-50	7556-7557	.	_

Text=The stop signal reaction time (SSRT) was computed by subtracting the critical SSD from the median go trial RT.
52-1	7558-7561	The	_
52-2	7562-7566	stop	_
52-3	7567-7573	signal	_
52-4	7574-7582	reaction	_
52-5	7583-7587	time	_
52-6	7588-7589	(	_
52-7	7590-7594	SSRT	_
52-8	7595-7596	)	_
52-9	7597-7600	was	_
52-10	7601-7609	computed	_
52-11	7610-7612	by	_
52-12	7613-7624	subtracting	_
52-13	7625-7628	the	_
52-14	7629-7637	critical	_
52-15	7638-7641	SSD	_
52-16	7642-7646	from	_
52-17	7647-7650	the	_
52-18	7651-7657	median	_
52-19	7658-7660	go	_
52-20	7661-7666	trial	_
52-21	7667-7669	RT	_
52-22	7670-7671	.	_

Text=It is known that in the SST the RT of a correct response is prolonged following a stop-error trial, compared with other correct responses, and this prolonged RT is thought to reflect error-detection and conflict monitoring (Hendrick et al., 2010).
53-1	7672-7674	It	_
53-2	7675-7677	is	_
53-3	7678-7683	known	_
53-4	7684-7688	that	_
53-5	7689-7691	in	_
53-6	7692-7695	the	_
53-7	7696-7699	SST	_
53-8	7700-7703	the	_
53-9	7704-7706	RT	_
53-10	7707-7709	of	_
53-11	7710-7711	a	_
53-12	7712-7719	correct	_
53-13	7720-7728	response	_
53-14	7729-7731	is	_
53-15	7732-7741	prolonged	_
53-16	7742-7751	following	_
53-17	7752-7753	a	_
53-18	7754-7764	stop-error	_
53-19	7765-7770	trial	_
53-20	7771-7772	,	_
53-21	7773-7781	compared	_
53-22	7782-7786	with	_
53-23	7787-7792	other	_
53-24	7793-7800	correct	_
53-25	7801-7810	responses	_
53-26	7811-7812	,	_
53-27	7813-7816	and	_
53-28	7817-7821	this	_
53-29	7822-7831	prolonged	_
53-30	7832-7834	RT	_
53-31	7835-7837	is	_
53-32	7838-7845	thought	_
53-33	7846-7848	to	_
53-34	7849-7856	reflect	_
53-35	7857-7872	error-detection	_
53-36	7873-7876	and	_
53-37	7877-7885	conflict	_
53-38	7886-7896	monitoring	_
53-39	7897-7898	(	_
53-40	7899-7907	Hendrick	_
53-41	7908-7910	et	_
53-42	7911-7914	al.	_
53-43	7915-7916	,	_
53-44	7917-7921	2010	_
53-45	7922-7923	)	_
53-46	7924-7925	.	_

Text=We thus compared the RT of the go trials that followed a stop-error trial and those that followed another go trial, and termed the effect size of this RT difference “ post-error slowing ” (PES).
54-1	7926-7928	We	_
54-2	7929-7933	thus	_
54-3	7934-7942	compared	_
54-4	7943-7946	the	_
54-5	7947-7949	RT	_
54-6	7950-7952	of	_
54-7	7953-7956	the	_
54-8	7957-7959	go	_
54-9	7960-7966	trials	_
54-10	7967-7971	that	_
54-11	7972-7980	followed	_
54-12	7981-7982	a	_
54-13	7983-7993	stop-error	_
54-14	7994-7999	trial	_
54-15	8000-8003	and	_
54-16	8004-8009	those	_
54-17	8010-8014	that	_
54-18	8015-8023	followed	_
54-19	8024-8031	another	_
54-20	8032-8034	go	_
54-21	8035-8040	trial	_
54-22	8041-8042	,	_
54-23	8043-8046	and	_
54-24	8047-8053	termed	_
54-25	8054-8057	the	_
54-26	8058-8064	effect	_
54-27	8065-8069	size	_
54-28	8070-8072	of	_
54-29	8073-8077	this	_
54-30	8078-8080	RT	_
54-31	8081-8091	difference	_
54-32	8092-8093	“	_
54-33	8094-8104	post-error	_
54-34	8105-8112	slowing	_
54-35	8113-8114	”	_
54-36	8115-8116	(	_
54-37	8117-8120	PES	_
54-38	8121-8122	)	_
54-39	8123-8124	.	_

Text=2.4 Image acquisition, preprocessing and statistical tests All imaging data were collected in the same 3T Siemens Trio scanner (Erlangen, Germany) while subjects performed the SST, as described in detail in our previous work.
55-1	8125-8128	2.4	_
55-2	8129-8134	Image	_
55-3	8135-8146	acquisition	_
55-4	8147-8148	,	_
55-5	8149-8162	preprocessing	_
55-6	8163-8166	and	_
55-7	8167-8178	statistical	_
55-8	8179-8184	tests	_
55-9	8185-8188	All	_
55-10	8189-8196	imaging	_
55-11	8197-8201	data	_
55-12	8202-8206	were	_
55-13	8207-8216	collected	_
55-14	8217-8219	in	_
55-15	8220-8223	the	_
55-16	8224-8228	same	_
55-17	8229-8231	3T	_
55-18	8232-8239	Siemens	_
55-19	8240-8244	Trio	_
55-20	8245-8252	scanner	_
55-21	8253-8254	(	_
55-22	8255-8263	Erlangen	_
55-23	8264-8265	,	_
55-24	8266-8273	Germany	_
55-25	8274-8275	)	_
55-26	8276-8281	while	_
55-27	8282-8290	subjects	_
55-28	8291-8300	performed	_
55-29	8301-8304	the	_
55-30	8305-8308	SST	_
55-31	8309-8310	,	_
55-32	8311-8313	as	_
55-33	8314-8323	described	_
55-34	8324-8326	in	_
55-35	8327-8333	detail	_
55-36	8334-8336	in	_
55-37	8337-8340	our	_
55-38	8341-8349	previous	_
55-39	8350-8354	work	_
55-40	8355-8356	.	_

Text=Each scan comprised four 10-minute runs of the SST.
56-1	8357-8361	Each	_
56-2	8362-8366	scan	_
56-3	8367-8376	comprised	_
56-4	8377-8381	four	_
56-5	8382-8391	10-minute	_
56-6	8392-8396	runs	_
56-7	8397-8399	of	_
56-8	8400-8403	the	_
56-9	8404-8407	SST	_
56-10	8408-8409	.	_

Text=Caffeine-using subjects were allowed drink coffee or other caffeinated beverages until 30 minutes before MRI.
57-1	8410-8424	Caffeine-using	_
57-2	8425-8433	subjects	_
57-3	8434-8438	were	_
57-4	8439-8446	allowed	_
57-5	8447-8452	drink	_
57-6	8453-8459	coffee	_
57-7	8460-8462	or	_
57-8	8463-8468	other	_
57-9	8469-8480	caffeinated	_
57-10	8481-8490	beverages	_
57-11	8491-8496	until	_
57-12	8497-8499	30	_
57-13	8500-8507	minutes	_
57-14	8508-8514	before	_
57-15	8515-8518	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
57-16	8519-8520	.	_

Text=Functional blood oxygenation-level dependent (BOLD) signals were acquired with a single-shot gradient echo echo-planar imaging sequence, with 32 axial slices parallel to the AC-PC line covering the whole brain, using published parameters: TR=2000 ms, TE=25 ms, bandwidth=2004 Hz/pixel, flip angle=85°, FOV=220×220 mm2, matrix=64×64, slice thickness=4 mm and no gap.
58-1	8521-8531	Functional	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
58-2	8532-8537	blood	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
58-3	8538-8555	oxygenation-level	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
58-4	8556-8565	dependent	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
58-5	8566-8567	(	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
58-6	8568-8572	BOLD	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
58-7	8573-8574	)	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
58-8	8575-8582	signals	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
58-9	8583-8587	were	_
58-10	8588-8596	acquired	_
58-11	8597-8601	with	_
58-12	8602-8603	a	_
58-13	8604-8615	single-shot	_
58-14	8616-8624	gradient	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
58-15	8625-8629	echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
58-16	8630-8641	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
58-17	8642-8649	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
58-18	8650-8658	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
58-19	8659-8660	,	_
58-20	8661-8665	with	_
58-21	8666-8668	32	_
58-22	8669-8674	axial	_
58-23	8675-8681	slices	_
58-24	8682-8690	parallel	_
58-25	8691-8693	to	_
58-26	8694-8697	the	_
58-27	8698-8703	AC-PC	_
58-28	8704-8708	line	_
58-29	8709-8717	covering	_
58-30	8718-8721	the	_
58-31	8722-8727	whole	_
58-32	8728-8733	brain	_
58-33	8734-8735	,	_
58-34	8736-8741	using	_
58-35	8742-8751	published	_
58-36	8752-8762	parameters	_
58-37	8763-8764	:	_
58-38	8765-8772	TR=2000	_
58-39	8773-8775	ms	_
58-40	8776-8777	,	_
58-41	8778-8783	TE=25	_
58-42	8784-8786	ms	_
58-43	8787-8788	,	_
58-44	8789-8803	bandwidth=2004	_
58-45	8804-8812	Hz/pixel	_
58-46	8813-8814	,	_
58-47	8815-8819	flip	_
58-48	8820-8829	angle=85°	_
58-49	8830-8831	,	_
58-50	8832-8843	FOV=220×220	_
58-51	8844-8847	mm2	_
58-52	8848-8849	,	_
58-53	8850-8862	matrix=64×64	_
58-54	8863-8864	,	_
58-55	8865-8870	slice	_
58-56	8871-8882	thickness=4	_
58-57	8883-8885	mm	_
58-58	8886-8889	and	_
58-59	8890-8892	no	_
58-60	8893-8896	gap	_
58-61	8897-8898	.	_

Text=A high-resolution 3D structural image (MPRAGE; 1 mm resolution) was also obtained for anatomical co-registration.
59-1	8899-8900	A	_
59-2	8901-8916	high-resolution	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
59-3	8917-8919	3D	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
59-4	8920-8930	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
59-5	8931-8936	image	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
59-6	8937-8938	(	_
59-7	8939-8945	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
59-8	8946-8947	;	_
59-9	8948-8949	1	_
59-10	8950-8952	mm	_
59-11	8953-8963	resolution	_
59-12	8964-8965	)	_
59-13	8966-8969	was	_
59-14	8970-8974	also	_
59-15	8975-8983	obtained	_
59-16	8984-8987	for	_
59-17	8988-8998	anatomical	_
59-18	8999-9014	co-registration	_
59-19	9015-9016	.	_

Text=Functional MRI data was preprocessed with Statistical Parametric Mapping 12 (SPM12) (Wellcome Department of Imaging Neuroscience, University College London, U.K.).
60-1	9017-9027	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
60-2	9028-9031	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
60-3	9032-9036	data	_
60-4	9037-9040	was	_
60-5	9041-9053	preprocessed	_
60-6	9054-9058	with	_
60-7	9059-9070	Statistical	_
60-8	9071-9081	Parametric	_
60-9	9082-9089	Mapping	_
60-10	9090-9092	12	_
60-11	9093-9094	(	_
60-12	9095-9100	SPM12	_
60-13	9101-9102	)	_
60-14	9103-9104	(	_
60-15	9105-9113	Wellcome	_
60-16	9114-9124	Department	_
60-17	9125-9127	of	_
60-18	9128-9135	Imaging	_
60-19	9136-9148	Neuroscience	_
60-20	9149-9150	,	_
60-21	9151-9161	University	_
60-22	9162-9169	College	_
60-23	9170-9176	London	_
60-24	9177-9178	,	_
60-25	9179-9183	U.K.	_
60-26	9184-9185	)	_
60-27	9186-9187	.	_

Text=Images from the first five TRs at the beginning of each trial were discarded so only BOLD signals in a steady state were included in analyses.
61-1	9188-9194	Images	_
61-2	9195-9199	from	_
61-3	9200-9203	the	_
61-4	9204-9209	first	_
61-5	9210-9214	five	_
61-6	9215-9218	TRs	_
61-7	9219-9221	at	_
61-8	9222-9225	the	_
61-9	9226-9235	beginning	_
61-10	9236-9238	of	_
61-11	9239-9243	each	_
61-12	9244-9249	trial	_
61-13	9250-9254	were	_
61-14	9255-9264	discarded	_
61-15	9265-9267	so	_
61-16	9268-9272	only	_
61-17	9273-9277	BOLD	_
61-18	9278-9285	signals	_
61-19	9286-9288	in	_
61-20	9289-9290	a	_
61-21	9291-9297	steady	_
61-22	9298-9303	state	_
61-23	9304-9308	were	_
61-24	9309-9317	included	_
61-25	9318-9320	in	_
61-26	9321-9329	analyses	_
61-27	9330-9331	.	_

Text=Images of each individual subject were first corrected for slice timing, realigned (motion-corrected).
62-1	9332-9338	Images	_
62-2	9339-9341	of	_
62-3	9342-9346	each	_
62-4	9347-9357	individual	_
62-5	9358-9365	subject	_
62-6	9366-9370	were	_
62-7	9371-9376	first	_
62-8	9377-9386	corrected	_
62-9	9387-9390	for	_
62-10	9391-9396	slice	_
62-11	9397-9403	timing	_
62-12	9404-9405	,	_
62-13	9406-9415	realigned	_
62-14	9416-9417	(	_
62-15	9418-9434	motion-corrected	_
62-16	9435-9436	)	_
62-17	9437-9438	.	_

Text=A mean functional image volume was constructed for each subject for each run from the realigned image volumes.
63-1	9439-9440	A	_
63-2	9441-9445	mean	_
63-3	9446-9456	functional	_
63-4	9457-9462	image	_
63-5	9463-9469	volume	_
63-6	9470-9473	was	_
63-7	9474-9485	constructed	_
63-8	9486-9489	for	_
63-9	9490-9494	each	_
63-10	9495-9502	subject	_
63-11	9503-9506	for	_
63-12	9507-9511	each	_
63-13	9512-9515	run	_
63-14	9516-9520	from	_
63-15	9521-9524	the	_
63-16	9525-9534	realigned	_
63-17	9535-9540	image	_
63-18	9541-9548	volumes	_
63-19	9549-9550	.	_

Text=The anatomical images (T1-weighted) were co-registered to the mean functional image, and normalized to an MNI (Montreal Neurological Institute) template with affine registration followed by nonlinear transformation using a unified segmentation and registration approach.
64-1	9551-9554	The	_
64-2	9555-9565	anatomical	_
64-3	9566-9572	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
64-4	9573-9574	(	_
64-5	9575-9586	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
64-6	9587-9588	)	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
64-7	9589-9593	were	_
64-8	9594-9607	co-registered	_
64-9	9608-9610	to	_
64-10	9611-9614	the	_
64-11	9615-9619	mean	_
64-12	9620-9630	functional	_
64-13	9631-9636	image	_
64-14	9637-9638	,	_
64-15	9639-9642	and	_
64-16	9643-9653	normalized	_
64-17	9654-9656	to	_
64-18	9657-9659	an	_
64-19	9660-9663	MNI	_
64-20	9664-9665	(	_
64-21	9666-9674	Montreal	_
64-22	9675-9687	Neurological	_
64-23	9688-9697	Institute	_
64-24	9698-9699	)	_
64-25	9700-9708	template	_
64-26	9709-9713	with	_
64-27	9714-9720	affine	_
64-28	9721-9733	registration	_
64-29	9734-9742	followed	_
64-30	9743-9745	by	_
64-31	9746-9755	nonlinear	_
64-32	9756-9770	transformation	_
64-33	9771-9776	using	_
64-34	9777-9778	a	_
64-35	9779-9786	unified	_
64-36	9787-9799	segmentation	_
64-37	9800-9803	and	_
64-38	9804-9816	registration	_
64-39	9817-9825	approach	_
64-40	9826-9827	.	_

Text=The normalization parameters determined for the anatomical volume were then applied to the corresponding functional image volumes for each subject.
65-1	9828-9831	The	_
65-2	9832-9845	normalization	_
65-3	9846-9856	parameters	_
65-4	9857-9867	determined	_
65-5	9868-9871	for	_
65-6	9872-9875	the	_
65-7	9876-9886	anatomical	_
65-8	9887-9893	volume	_
65-9	9894-9898	were	_
65-10	9899-9903	then	_
65-11	9904-9911	applied	_
65-12	9912-9914	to	_
65-13	9915-9918	the	_
65-14	9919-9932	corresponding	_
65-15	9933-9943	functional	_
65-16	9944-9949	image	_
65-17	9950-9957	volumes	_
65-18	9958-9961	for	_
65-19	9962-9966	each	_
65-20	9967-9974	subject	_
65-21	9975-9976	.	_

Text=Finally, images were smoothed with a Gaussian kernel of 8 mm at Full Width at Half Maximum.
66-1	9977-9984	Finally	_
66-2	9985-9986	,	_
66-3	9987-9993	images	_
66-4	9994-9998	were	_
66-5	9999-10007	smoothed	_
66-6	10008-10012	with	_
66-7	10013-10014	a	_
66-8	10015-10023	Gaussian	_
66-9	10024-10030	kernel	_
66-10	10031-10033	of	_
66-11	10034-10035	8	_
66-12	10036-10038	mm	_
66-13	10039-10041	at	_
66-14	10042-10046	Full	_
66-15	10047-10052	Width	_
66-16	10053-10055	at	_
66-17	10056-10060	Half	_
66-18	10061-10068	Maximum	_
66-19	10069-10070	.	_

Text=Images from the first five TRs at the beginning of each session were discarded so only signals with steady-state equilibrium between radio frequency pulsing and relaxation were included in data analyses.
67-1	10071-10077	Images	_
67-2	10078-10082	from	_
67-3	10083-10086	the	_
67-4	10087-10092	first	_
67-5	10093-10097	five	_
67-6	10098-10101	TRs	_
67-7	10102-10104	at	_
67-8	10105-10108	the	_
67-9	10109-10118	beginning	_
67-10	10119-10121	of	_
67-11	10122-10126	each	_
67-12	10127-10134	session	_
67-13	10135-10139	were	_
67-14	10140-10149	discarded	_
67-15	10150-10152	so	_
67-16	10153-10157	only	_
67-17	10158-10165	signals	_
67-18	10166-10170	with	_
67-19	10171-10183	steady-state	_
67-20	10184-10195	equilibrium	_
67-21	10196-10203	between	_
67-22	10204-10209	radio	_
67-23	10210-10219	frequency	_
67-24	10220-10227	pulsing	_
67-25	10228-10231	and	_
67-26	10232-10242	relaxation	_
67-27	10243-10247	were	_
67-28	10248-10256	included	_
67-29	10257-10259	in	_
67-30	10260-10264	data	_
67-31	10265-10273	analyses	_
67-32	10274-10275	.	_

Text=We distinguished four trial outcomes in this event-related study: go success (GS), go error, stop success (SS), and stop error (SE), and modeled BOLD signals by convolving the onsets of the go signals of each trial with a canonical hemodynamic response function (HRF) and the temporal derivative of the canonical HRF.
68-1	10276-10278	We	_
68-2	10279-10292	distinguished	_
68-3	10293-10297	four	_
68-4	10298-10303	trial	_
68-5	10304-10312	outcomes	_
68-6	10313-10315	in	_
68-7	10316-10320	this	_
68-8	10321-10334	event-related	_
68-9	10335-10340	study	_
68-10	10341-10342	:	_
68-11	10343-10345	go	_
68-12	10346-10353	success	_
68-13	10354-10355	(	_
68-14	10356-10358	GS	_
68-15	10359-10360	)	_
68-16	10361-10362	,	_
68-17	10363-10365	go	_
68-18	10366-10371	error	_
68-19	10372-10373	,	_
68-20	10374-10378	stop	_
68-21	10379-10386	success	_
68-22	10387-10388	(	_
68-23	10389-10391	SS	_
68-24	10392-10393	)	_
68-25	10394-10395	,	_
68-26	10396-10399	and	_
68-27	10400-10404	stop	_
68-28	10405-10410	error	_
68-29	10411-10412	(	_
68-30	10413-10415	SE	_
68-31	10416-10417	)	_
68-32	10418-10419	,	_
68-33	10420-10423	and	_
68-34	10424-10431	modeled	_
68-35	10432-10436	BOLD	_
68-36	10437-10444	signals	_
68-37	10445-10447	by	_
68-38	10448-10458	convolving	_
68-39	10459-10462	the	_
68-40	10463-10469	onsets	_
68-41	10470-10472	of	_
68-42	10473-10476	the	_
68-43	10477-10479	go	_
68-44	10480-10487	signals	_
68-45	10488-10490	of	_
68-46	10491-10495	each	_
68-47	10496-10501	trial	_
68-48	10502-10506	with	_
68-49	10507-10508	a	_
68-50	10509-10518	canonical	_
68-51	10519-10530	hemodynamic	_
68-52	10531-10539	response	_
68-53	10540-10548	function	_
68-54	10549-10550	(	_
68-55	10551-10554	HRF	_
68-56	10555-10556	)	_
68-57	10557-10560	and	_
68-58	10561-10564	the	_
68-59	10565-10573	temporal	_
68-60	10574-10584	derivative	_
68-61	10585-10587	of	_
68-62	10588-10591	the	_
68-63	10592-10601	canonical	_
68-64	10602-10605	HRF	_
68-65	10606-10607	.	_

Text=Realignment parameters in all six dimensions were entered in the model.
69-1	10608-10619	Realignment	_
69-2	10620-10630	parameters	_
69-3	10631-10633	in	_
69-4	10634-10637	all	_
69-5	10638-10641	six	_
69-6	10642-10652	dimensions	_
69-7	10653-10657	were	_
69-8	10658-10665	entered	_
69-9	10666-10668	in	_
69-10	10669-10672	the	_
69-11	10673-10678	model	_
69-12	10679-10680	.	_

Text=We included the following variables as parametric modulators in the model: RT of GS trials, SSD of SS trials, and SSD of SE trials, in that order.
70-1	10681-10683	We	_
70-2	10684-10692	included	_
70-3	10693-10696	the	_
70-4	10697-10706	following	_
70-5	10707-10716	variables	_
70-6	10717-10719	as	_
70-7	10720-10730	parametric	_
70-8	10731-10741	modulators	_
70-9	10742-10744	in	_
70-10	10745-10748	the	_
70-11	10749-10754	model	_
70-12	10755-10756	:	_
70-13	10757-10759	RT	_
70-14	10760-10762	of	_
70-15	10763-10765	GS	_
70-16	10766-10772	trials	_
70-17	10773-10774	,	_
70-18	10775-10778	SSD	_
70-19	10779-10781	of	_
70-20	10782-10784	SS	_
70-21	10785-10791	trials	_
70-22	10792-10793	,	_
70-23	10794-10797	and	_
70-24	10798-10801	SSD	_
70-25	10802-10804	of	_
70-26	10805-10807	SE	_
70-27	10808-10814	trials	_
70-28	10815-10816	,	_
70-29	10817-10819	in	_
70-30	10820-10824	that	_
70-31	10825-10830	order	_
70-32	10831-10832	.	_

Text=Serial autocorrelation of the time series was corrected by a first degree autoregressive or AR model.
71-1	10833-10839	Serial	_
71-2	10840-10855	autocorrelation	_
71-3	10856-10858	of	_
71-4	10859-10862	the	_
71-5	10863-10867	time	_
71-6	10868-10874	series	_
71-7	10875-10878	was	_
71-8	10879-10888	corrected	_
71-9	10889-10891	by	_
71-10	10892-10893	a	_
71-11	10894-10899	first	_
71-12	10900-10906	degree	_
71-13	10907-10921	autoregressive	_
71-14	10922-10924	or	_
71-15	10925-10927	AR	_
71-16	10928-10933	model	_
71-17	10934-10935	.	_

Text=The data were high- pass filtered (1/128 Hz cutoff) to remove low-frequency signal drifts.
72-1	10936-10939	The	_
72-2	10940-10944	data	_
72-3	10945-10949	were	_
72-4	10950-10955	high-	_
72-5	10956-10960	pass	_
72-6	10961-10969	filtered	_
72-7	10970-10971	(	_
72-8	10972-10977	1/128	_
72-9	10978-10980	Hz	_
72-10	10981-10987	cutoff	_
72-11	10988-10989	)	_
72-12	10990-10992	to	_
72-13	10993-10999	remove	_
72-14	11000-11013	low-frequency	_
72-15	11014-11020	signal	_
72-16	11021-11027	drifts	_
72-17	11028-11029	.	_

Text=Group analyses were performed also using SPM12 on the error contrast maps (SE> GS) using one and two sample t-tests and multiple regressions, with age as covariate.
73-1	11030-11035	Group	_
73-2	11036-11044	analyses	_
73-3	11045-11049	were	_
73-4	11050-11059	performed	_
73-5	11060-11064	also	_
73-6	11065-11070	using	_
73-7	11071-11076	SPM12	_
73-8	11077-11079	on	_
73-9	11080-11083	the	_
73-10	11084-11089	error	_
73-11	11090-11098	contrast	_
73-12	11099-11103	maps	_
73-13	11104-11105	(	_
73-14	11106-11108	SE	_
73-15	11109-11110	>	_
73-16	11111-11113	GS	_
73-17	11114-11115	)	_
73-18	11116-11121	using	_
73-19	11122-11125	one	_
73-20	11126-11129	and	_
73-21	11130-11133	two	_
73-22	11134-11140	sample	_
73-23	11141-11148	t-tests	_
73-24	11149-11152	and	_
73-25	11153-11161	multiple	_
73-26	11162-11173	regressions	_
73-27	11174-11175	,	_
73-28	11176-11180	with	_
73-29	11181-11184	age	_
73-30	11185-11187	as	_
73-31	11188-11197	covariate	_
73-32	11198-11199	.	_

Text=Specifically, we employed a whole-brain regression against AUDIT score to examine regional responses to errors in association with problem drinking for men and women separately.
74-1	11200-11212	Specifically	_
74-2	11213-11214	,	_
74-3	11215-11217	we	_
74-4	11218-11226	employed	_
74-5	11227-11228	a	_
74-6	11229-11240	whole-brain	_
74-7	11241-11251	regression	_
74-8	11252-11259	against	_
74-9	11260-11265	AUDIT	_
74-10	11266-11271	score	_
74-11	11272-11274	to	_
74-12	11275-11282	examine	_
74-13	11283-11291	regional	_
74-14	11292-11301	responses	_
74-15	11302-11304	to	_
74-16	11305-11311	errors	_
74-17	11312-11314	in	_
74-18	11315-11326	association	_
74-19	11327-11331	with	_
74-20	11332-11339	problem	_
74-21	11340-11348	drinking	_
74-22	11349-11352	for	_
74-23	11353-11356	men	_
74-24	11357-11360	and	_
74-25	11361-11366	women	_
74-26	11367-11377	separately	_
74-27	11378-11379	.	_

Text=All group analyses were examined with a threshold of voxel p <0.001 uncorrected in combination with cluster p <0.05, FWE corrected, according to current reporting standards.
75-1	11380-11383	All	_
75-2	11384-11389	group	_
75-3	11390-11398	analyses	_
75-4	11399-11403	were	_
75-5	11404-11412	examined	_
75-6	11413-11417	with	_
75-7	11418-11419	a	_
75-8	11420-11429	threshold	_
75-9	11430-11432	of	_
75-10	11433-11438	voxel	_
75-11	11439-11440	p	_
75-12	11441-11442	<	_
75-13	11443-11448	0.001	_
75-14	11449-11460	uncorrected	_
75-15	11461-11463	in	_
75-16	11464-11475	combination	_
75-17	11476-11480	with	_
75-18	11481-11488	cluster	_
75-19	11489-11490	p	_
75-20	11491-11492	<	_
75-21	11493-11497	0.05	_
75-22	11498-11499	,	_
75-23	11500-11503	FWE	_
75-24	11504-11513	corrected	_
75-25	11514-11515	,	_
75-26	11516-11525	according	_
75-27	11526-11528	to	_
75-28	11529-11536	current	_
75-29	11537-11546	reporting	_
75-30	11547-11556	standards	_
75-31	11557-11558	.	_

